Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Hyperlipoproteinemias

  Free Subscription


Articles published in Atherosclerosis

Retrieve available abstracts of 90 articles:
HTML format



Single Articles


    May 2022
  1. CHEMELLO K, Chan DC, Lambert G, Watts GF, et al
    Recent advances in demystifying the metabolism of lipoprotein(a).
    Atherosclerosis. 2022;349:82-91.
    PubMed     Abstract available


  2. PEDERIVA C, Capra ME, Biasucci G, Banderali G, et al
    Lipoprotein(a) and family history for cardiovascular disease in paediatric patients: A new frontier in cardiovascular risk stratification. Data from the LIPIGEN paediatric group.
    Atherosclerosis. 2022;349:233-239.
    PubMed     Abstract available


  3. RIDER DA, Eisermann M, Loffler K, Aleku M, et al
    Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease.
    Atherosclerosis. 2022;349:240-247.
    PubMed     Abstract available


    April 2022
  4. TENG H, Gao Y, Wu C, Zhang H, et al
    Prevalence and patient characteristics of familial hypercholesterolemia in a Chinese population aged 35-75 years: Results from China PEACE Million Persons Project.
    Atherosclerosis. 2022;350:58-64.
    PubMed     Abstract available


    March 2022
  5. NOTO D, Spina R, Giammanco A, Barbagallo CM, et al
    Diagnosis of familial hypercholesterolemia in a large cohort of Italian genotyped hypercholesterolemic patients.
    Atherosclerosis. 2022;347:63-67.
    PubMed     Abstract available


  6. MULDER JWCM, Kranenburg LW, Treling WJ, Hovingh GK, et al
    Quality of life and coping in Dutch homozygous familial hypercholesterolemia patients: A qualitative study.
    Atherosclerosis. 2022 Mar 12. pii: S0021-9150(22)00136.
    PubMed     Abstract available


    February 2022
  7. STOCK JK
    Homozygous Familial Hypercholesterolaemia International Clinical Collaboration (HICC) registry: Levelling up access to treatment urgently needed.
    Atherosclerosis. 2022 Feb 20. pii: S0021-9150(22)00077.
    PubMed    


    January 2022
  8. PAQUETTE M, Baass A
    Polygenic risk scores for cardiovascular disease prediction in the clinical practice: Are we there?
    Atherosclerosis. 2022;340:46-47.
    PubMed    


    December 2021
  9. TRINDER M, Vikulova D, Pimstone S, Mancini GBJ, et al
    Polygenic architecture and cardiovascular risk of familial combined hyperlipidemia.
    Atherosclerosis. 2021;340:35-43.
    PubMed     Abstract available


  10. TADA H, Okada H, Nohara A, Takamura M, et al
    Genetic mutations, regression of Achilles tendon thickness, and cardiovascular events among patients with familial hypercholesterolemia.
    Atherosclerosis. 2021;340:28-34.
    PubMed     Abstract available


    November 2021
  11. CHAKRABORTY A, Pang J, Chan DC, Ellis KL, et al
    Cascade testing for elevated lipoprotein(a) in relatives of probands with familial hypercholesterolaemia and elevated lipoprotein(a).
    Atherosclerosis. 2021 Nov 12. pii: S0021-9150(21)01417.
    PubMed     Abstract available


  12. SANCHEZ-RAMOS A, Fernandez-Labandera C, Vallejo-Vaz A, Bonacho EC, et al
    Prevalence of familial hypercholesterolemia phenotype and ten-year risk of cardiovascular events in a working population in primary prevention: The ICARIA study.
    Atherosclerosis. 2021;338:39-45.
    PubMed     Abstract available


  13. TROMP TR, Cupido AJ, Reeskamp LF, Stroes ESG, et al
    Assessment of practical applicability and clinical relevance of a commonly used LDL-C polygenic score in patients with severe hypercholesterolemia.
    Atherosclerosis. 2021 Nov 2. pii: S0021-9150(21)01413.
    PubMed     Abstract available


    October 2021
  14. LEONARDI-BEE J, Boateng C, Faria R, Eliman K, et al
    Effectiveness of cascade testing strategies in relatives for familial hypercholesterolemia: A systematic review and meta-analysis.
    Atherosclerosis. 2021;338:7-14.
    PubMed     Abstract available


    September 2021
  15. STOCK JK
    Global Familial Hypercholesterolaemia Studies Collaboration (FHSC).
    Atherosclerosis. 2021 Sep 23. pii: S0021-9150(21)01361.
    PubMed    


  16. PAQUETTE M, Bernard S, Baass A
    Hemoglobin concentration, hematocrit and red blood cell count predict major adverse cardiovascular events in patients with familial hypercholesterolemia.
    Atherosclerosis. 2021;335:41-46.
    PubMed     Abstract available


  17. KLEVMOEN M, Bogsrud MP, Retterstol K, Svilaas T, et al
    Loss of statin treatment years during pregnancy and breastfeeding periods in women with familial hypercholesterolemia.
    Atherosclerosis. 2021;335:8-15.
    PubMed     Abstract available


    August 2021
  18. MARCO-BENEDI V, Cenarro A, Laclaustra M, Larrea-Sebal A, et al
    Lipoprotein(a) in hereditary hypercholesterolemia: Influence of the genetic cause, defective gene and type of mutation.
    Atherosclerosis. 2021 Aug 23. pii: S0021-9150(21)01270.
    PubMed     Abstract available


  19. DYRBUS K, Gasior M, Desperak P, Trzeciak P, et al
    Risk-factors associated with extremely high cardiovascular risk of mid- and long-term mortality following myocardial infarction: Analysis of the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) registry.
    Atherosclerosis. 2021;333:16-23.
    PubMed     Abstract available


  20. TOMBLING BJ, Zhang Y, Huang YH, Craik DJ, et al
    The emerging landscape of peptide-based inhibitors of PCSK9.
    Atherosclerosis. 2021;330:52-60.
    PubMed     Abstract available


    July 2021
  21. KATZMANN JL, Lehmann M, Tunnemann-Tarr A, An Haack I, et al
    Cutaneous manifestations in familial hypercholesterolaemia.
    Atherosclerosis. 2021 Jul 11. pii: S0021-9150(21)01236.
    PubMed     Abstract available


  22. KHALIL YA, Rabes JP, Boileau C, Varret M, et al
    APOE gene variants in primary dyslipidemia.
    Atherosclerosis. 2021;328:11-22.
    PubMed     Abstract available


  23. ALVES AC, Azevedo S, Benito-Vicente A, Graca R, et al
    LDLR variants functional characterization: Contribution to variant classification.
    Atherosclerosis. 2021;329:14-21.
    PubMed     Abstract available


    June 2021
  24. MALO AI, Girona J, Ibarretxe D, Rodriguez-Borjabad C, et al
    Serum glycoproteins A and B assessed by (1)H-NMR in familial hypercholesterolemia.
    Atherosclerosis. 2021;330:1-7.
    PubMed     Abstract available


  25. PAQUETTE M, Fantino M, Bernard S, Baass A, et al
    Paternal inheritance predicts earlier cardiovascular event onset in patients with familial hypercholesterolemia.
    Atherosclerosis. 2021;329:9-13.
    PubMed     Abstract available


  26. ROOS CM, Zhang B, Hagler MA, Arghami A, et al
    MnSOD protects against vascular calcification independent of changes in vascular function in hypercholesterolemic mice.
    Atherosclerosis. 2021 Jun 8. pii: S0021-9150(21)00276.
    PubMed     Abstract available


    May 2021
  27. REESKAMP LF, Nurmohamed NS, Bom MJ, Planken RN, et al
    Marked plaque regression in homozygous familial hypercholesterolemia.
    Atherosclerosis. 2021;327:13-17.
    PubMed     Abstract available


    April 2021
  28. BRANDTS J, Dharmayat KI, Vallejo-Vaz AJ, Azar Sharabiani MT, et al
    A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia.
    Atherosclerosis. 2021;325:46-56.
    PubMed     Abstract available


  29. INGOE L, Potter A, Musson S, Neely D, et al
    Improving the identification of patients with a genetic diagnosis of familial hypercholesterolaemia in primary care: A strategy to achieve the NHS long term plan.
    Atherosclerosis. 2021;325:38-45.
    PubMed     Abstract available


  30. SUADONI MT
    Benefits and harms of LDL-cholesterol-lowering therapy in older people must be established through valid and clinically relevant evidence.
    Atherosclerosis. 2021;323:57-58.
    PubMed    


  31. LIMA JG, Helena C Nobrega L, Moura Bandeira FT, Pires Sousa AG, et al
    A novel GPIHBP1 mutation related to familial chylomicronemia syndrome: A series of cases.
    Atherosclerosis. 2021;322:31-38.
    PubMed     Abstract available


  32. JO SH, Han SH, Kim SH, Eckel RH, et al
    Cardiovascular effects of omega-3 fatty acids: Hope or hype?
    Atherosclerosis. 2021;322:15-23.
    PubMed     Abstract available


    March 2021
  33. BUONUOMO PS, Mastrogiorgio G, Leone G, Rana I, et al
    Evolocumab in the management of children <10 years of age affected by homozygous familial hypercholesterolemia.
    Atherosclerosis. 2021 Mar 28. pii: S0021-9150(21)00147.
    PubMed    


  34. ELLINS EA, Watkins S, Rees DA, Datta DBN, et al
    Acute effect of a single session of lipoprotein apheresis on central haemodynamics in patients with familial hypercholesterolaemia.
    Atherosclerosis. 2021 Mar 27. pii: S0021-9150(21)00144.
    PubMed    


  35. BIESECKER LG
    Correspondence on: "Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features".
    Atherosclerosis. 2021 Mar 20. pii: S0021-9150(21)00125.
    PubMed    


  36. ZIGMOND ZM, Song L, Martinez L, Lassance-Soares RM, et al
    c-Kit expression in smooth muscle cells reduces atherosclerosis burden in hyperlipidemic mice.
    Atherosclerosis. 2021 Mar 9. pii: S0021-9150(21)00112.
    PubMed     Abstract available


  37. BANACH M, Penson PE
    Lipid-lowering therapies: Better together.
    Atherosclerosis. 2021;320:86-88.
    PubMed    


    February 2021
  38. LEREN TP, Bogsrud MP
    Molecular genetic testing for autosomal dominant hypercholesterolemia in 29,449 Norwegian index patients and 14,230 relatives during the years 1993-2020.
    Atherosclerosis. 2021;322:61-66.
    PubMed     Abstract available


  39. REESKAMP LF, Balvers M, Peter J, van de Kerkhof L, et al
    Intronic variant screening with targeted next-generation sequencing reveals first pseudoexon in LDLR in familial hypercholesterolemia.
    Atherosclerosis. 2021;321:14-20.
    PubMed     Abstract available


    January 2021
  40. VUORIO A, Raal F, Kaste M, Kovanen PT, et al
    Familial hypercholesterolaemia and COVID-19: A two-hit scenario for endothelial dysfunction amenable to treatment.
    Atherosclerosis. 2021;320:53-60.
    PubMed     Abstract available


  41. MARCO-BENEDI V, Laclaustra M, Bea AM, Suarez-Tembra M, et al
    Maternally inherited hypercholesterolemia does not modify the cardiovascular phenotype in familial hypercholesterolemia.
    Atherosclerosis. 2021;320:47-52.
    PubMed     Abstract available


  42. FUTEMA M, Ramaswami U, Tichy L, Bogsrud MP, et al
    Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries.
    Atherosclerosis. 2021;319:108-117.
    PubMed     Abstract available


  43. GAUTIER T, Deckert V, Aires V, Le Guern N, et al
    Human apolipoprotein C1 transgenesis reduces atherogenesis in hypercholesterolemic rabbits.
    Atherosclerosis. 2021;320:10-18.
    PubMed     Abstract available


  44. VALLEJO-VAZ AJ, Packard CJ, Ference BA, Santos RD, et al
    LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial.
    Atherosclerosis. 2021;320:1-9.
    PubMed     Abstract available


  45. KOROSOGLOU G, Chatzizisis YS, Raggi P
    Coronary computed tomography angiography in asymptomatic patients: Still a taboo or precision medicine?
    Atherosclerosis. 2021;317:47-49.
    PubMed    


  46. STOCK JK
    Should we treat high LDL cholesterol in 'healthy' elderly individuals?
    Atherosclerosis. 2021;317:50-51.
    PubMed    


    December 2020
  47. RUBINO J, MacDougall DE, Sterling LR, Hanselman JC, et al
    Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial.
    Atherosclerosis. 2020 Dec 31. pii: S0021-9150(20)31597.
    PubMed     Abstract available


  48. SVENDSEN K, Krogh HW, Igland J, Tell GS, et al
    2.5-fold increased risk of recurrent acute myocardial infarction with familial hypercholesterolemia.
    Atherosclerosis. 2020;319:28-34.
    PubMed     Abstract available


  49. COUTINHO ER, Miname MH, Rocha VZ, Bittencourt MS, et al
    Familial hypercholesterolemia and cardiovascular disease in older individuals.
    Atherosclerosis. 2020;318:32-37.
    PubMed     Abstract available


  50. SVENDSEN K, Langslet G, Krogh HW, Brinck J, et al
    Genetic testing is essential for initiating statin therapy in children with familial hypercholesterolemia: Examples from Scandinavia.
    Atherosclerosis. 2020;316:48-52.
    PubMed     Abstract available


    November 2020
  51. REESKAMP LF, Tromp TR, Huijgen R, Stroes ESG, et al
    Statin therapy reduces plasma angiopoietin-like 3 (ANGPTL3) concentrations in hypercholesterolemic patients via reduced liver X receptor (LXR) activation.
    Atherosclerosis. 2020;315:68-75.
    PubMed     Abstract available


  52. PEREZ DE ISLA L, Alonso R, Gomez de Diego JJ, Muniz-Grijalvo O, et al
    Coronary plaque burden, plaque characterization and their prognostic implications in familial hypercholesterolemia: A computed tomographic angiography study.
    Atherosclerosis. 2020 Nov 18. pii: S0021-9150(20)31521.
    PubMed     Abstract available


    October 2020
  53. IYEN B, Qureshi N, Weng S, Roderick P, et al
    Sex differences in cardiovascular morbidity associated with familial hypercholesterolaemia: A retrospective cohort study of the UK Simon Broome register linked to national hospital records.
    Atherosclerosis. 2020 Oct 31. pii: S0021-9150(20)31491.
    PubMed     Abstract available


    September 2020
  54. BURRIS RL, Vick SC, Popovic B, Fraungruber PE, et al
    Maternal exposure to soy diet reduces atheroma in hyperlipidemic F1 offspring mice by promoting macrophage and T cell anti-inflammatory responses.
    Atherosclerosis. 2020;313:26-34.
    PubMed     Abstract available


  55. IQBAL Z, Ho JH, Adam S, France M, et al
    Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK.
    Atherosclerosis. 2020;313:126-136.
    PubMed     Abstract available


  56. BERTOLINI S, Calandra S, Arca M, Averna M, et al
    Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features.
    Atherosclerosis. 2020;312:72-78.
    PubMed     Abstract available


    August 2020
  57. MULORZ J, Spin JM, Beck HC, Tha Thi ML, et al
    Hyperlipidemia does not affect development of elastase-induced abdominal aortic aneurysm in mice.
    Atherosclerosis. 2020;311:73-83.
    PubMed     Abstract available


  58. RODRIGUEZ-NOVOA S, Rodriguez-Jimenez C, Alonso C, Rodriguez-Laguna L, et al
    Familial hypercholesterolemia: A single-nucleotide variant (SNV) in mosaic at the low density lipoprotein receptor (LDLR).
    Atherosclerosis. 2020;311:37-43.
    PubMed     Abstract available


  59. PEPPLINKHUIZEN S, Ibrahim S, Vink R, Groot B, et al
    Electronic health records to facilitate continuous detection of familial hypercholesterolemia.
    Atherosclerosis. 2020;310:83-87.
    PubMed     Abstract available


  60. ALJENEDIL S, Alothman L, Belanger AM, Brown L, et al
    Lomitapide for treatment of homozygous familial hypercholesterolemia: The Quebec experience.
    Atherosclerosis. 2020;310:54-63.
    PubMed     Abstract available


    July 2020
  61. RALLIDIS LS, Liberopoulos EN, Vlachopoulos C, Skoumas I, et al
    Very high-risk familial hypercholesterolaemia patients in real life: The remaining gap in achieving the current LDL-C targets despite the use of PCSK9 inhibitors.
    Atherosclerosis. 2020 Jul 30. pii: S0021-9150(20)30385.
    PubMed    


  62. PASTA A, Cremonini AL, Formisano E, Fresa R, et al
    Long term follow-up of genetically confirmed patients with familial hypercholesterolemia treated with first and second-generation statins and then with PCSK9 monoclonal antibodies.
    Atherosclerosis. 2020;308:6-14.
    PubMed     Abstract available


  63. GULIZIA MM, Maggioni AP, Abrignani MG, Bilato C, et al
    Prevalence Of familial hypercholeSTerolaemia (FH) in Italian Patients with coronary artERy disease: The POSTER study.
    Atherosclerosis. 2020;308:32-38.
    PubMed     Abstract available


  64. FUKUMOTO K, Takemoto Y, Yoshikawa J, Norioka N, et al
    Predictors of endothelial function improvement in patients with mild hypertriglyceridemia without evidence of coronary artery disease treated with purified eicosapentaenoic acid.
    Atherosclerosis. 2020;309:27-32.
    PubMed     Abstract available


  65. STOCK J
    Familial hypercholesterolemia: An urgent public health priority.
    Atherosclerosis. 2020 Jul 18. pii: S0021-9150(20)30351.
    PubMed    


  66. GALLO A, Charriere S, Vimont A, Chapman MJ, et al
    SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia.
    Atherosclerosis. 2020;306:41-49.
    PubMed     Abstract available


    May 2020
  67. LAU P, Soubeyrand S, Hegele RA, Lagace TA, et al
    Molecular mechanism linking a novel PCSK9 copy number variant to severe hypercholesterolemia.
    Atherosclerosis. 2020;304:39-43.
    PubMed     Abstract available


  68. STOCK JK
    Homozygous familial hypercholesterolaemia: New hope for getting patients to goal?
    Atherosclerosis. 2020 May 25. pii: S0021-9150(20)30230.
    PubMed    


  69. ADEMI Z, Norman R, Pang J, Liew D, et al
    Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?
    Atherosclerosis. 2020;304:1-8.
    PubMed     Abstract available


  70. TSIMIKAS S, Stroes ESG
    The dedicated "Lp(a) clinic": A concept whose time has arrived?
    Atherosclerosis. 2020;300:1-9.
    PubMed     Abstract available


  71. DE NISCO G, Hoogendoorn A, Chiastra C, Gallo D, et al
    The impact of helical flow on coronary atherosclerotic plaque development.
    Atherosclerosis. 2020;300:39-46.
    PubMed     Abstract available


    March 2020
  72. PANG J, Abraham A, Vargas-Garcia C, Bates TR, et al
    An age-matched computed tomography angiographic study of coronary atherosclerotic plaques in patients with familial hypercholesterolaemia.
    Atherosclerosis. 2020;298:52-57.
    PubMed     Abstract available


  73. ADINOLFI LE, Petta S, Fracanzani AL, Coppola C, et al
    Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study.
    Atherosclerosis. 2020;296:40-47.
    PubMed     Abstract available


    February 2020
  74. LUIRINK IK, Hutten BA, Greber-Platzer S, Kolovou GD, et al
    Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia: Data from an international registry.
    Atherosclerosis. 2020;299:24-31.
    PubMed     Abstract available


  75. NORDESTGAARD BG, Langlois MR, Langsted A, Chapman MJ, et al
    Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM.
    Atherosclerosis. 2020;294:46-61.
    PubMed     Abstract available


    January 2020
  76. CHIU YW, Wu CS, Chen PC, Wei YC, et al
    Risk of acute mesenteric ischemia in patients with diabetes: A population-based cohort study in Taiwan.
    Atherosclerosis. 2020;296:18-24.
    PubMed     Abstract available


    December 2019
  77. FULLER DT, Grainger AT, Manichaikul A, Shi W, et al
    Genetic linkage of oxidative stress with cardiometabolic traits in an intercross derived from hyperlipidemic mouse strains.
    Atherosclerosis. 2019;293:1-10.
    PubMed     Abstract available


    November 2019
  78. MULDER JWCM, Galema-Boers AMH, de Jong-Verweij LM, Hazelzet JA, et al
    The development and first results of a health-related outcomes set in familial hypercholesterolemia (FH) patients: Knowledge is health.
    Atherosclerosis. 2019;293:11-17.
    PubMed     Abstract available


  79. LAMIQUIZ-MONEO I, Restrepo-Cordoba MA, Mateo-Gallego R, Bea AM, et al
    Predicted pathogenic mutations in STAP1 are not associated with clinically defined familial hypercholesterolemia.
    Atherosclerosis. 2019;292:143-151.
    PubMed     Abstract available


  80. WALD DS, Bestwick JP
    Reaching detection targets in familial hypercholesterolaemia: Comparison of identification strategies.
    Atherosclerosis. 2019;293:57-61.
    PubMed     Abstract available


  81. RAMASWAMI U, Futema M, Bogsrud MP, Holven KB, et al
    Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries.
    Atherosclerosis. 2019;292:178-187.
    PubMed     Abstract available


    October 2019
  82. RAMOS R, Masana L, Comas-Cufi M, Garcia-Gil M, et al
    Derivation and validation of SIDIAP-FHP score: A new risk model predicting cardiovascular disease in familial hypercholesterolemia phenotype.
    Atherosclerosis. 2019;292:42-51.
    PubMed     Abstract available


  83. CAO YX, Jin JL, Guo YL, Sun D, et al
    Baseline and on-statin treatment lipoprotein(a) levels for predicting cardiovascular events in patients with familial hypercholesterolemia.
    Atherosclerosis. 2019;291:27-33.
    PubMed     Abstract available


    September 2019
  84. STOCK J
    First insights from the EAS familial hypercholesterolaemia collaboration registry: FH is still underdiagnosed and undertreated.
    Atherosclerosis. 2019 Sep 28. pii: S0021-9150(19)31502.
    PubMed    


  85. LEON-ACUNA A, Torres-Pena JD, Alcala-Diaz JF, Vals-Delgado C, et al
    Lifestyle factors modulate postprandial hypertriglyceridemia: From the CORDIOPREV study.
    Atherosclerosis. 2019;290:118-124.
    PubMed     Abstract available


  86. NAGARAJAN UM, Sikes JD, Burris RL, Jha R, et al
    Genital Chlamydia infection in hyperlipidemic mouse models exacerbates atherosclerosis.
    Atherosclerosis. 2019;290:103-110.
    PubMed     Abstract available


    July 2019
  87. LANGSTED A, Vedel-Krogh S, Kobylecki CJ, Nordestgaard BG, et al
    Reply to: "Seasonal variations of lipid profiles in a French cohort".
    Atherosclerosis. 2019;286:184-186.
    PubMed    


  88. NADIF R, Goldberg S, Gourmelen J, Ozguler A, et al
    Seasonal variations of lipid profiles in a French cohort.
    Atherosclerosis. 2019;286:181-183.
    PubMed    


    April 2019
  89. ALOTHMAN L, Genest J
    Chylomicrons: When you can't direct the wind, adjust the sail.
    Atherosclerosis. 2019;283:121-123.
    PubMed    


    January 2019
  90. YAN Y, He F, Li Z, Xu R, et al
    The important role of apolipoprotein A-II in ezetimibe driven reduction of high cholesterol diet-induced atherosclerosis.
    Atherosclerosis. 2019;280:99-108.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hyperlipoproteinemias is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: